An observational study in Strongyloidiasis and Bone Marrow Transplant Infection, sponsored by Imperial College Healthcare NHS Trust. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-14.
Sponsored by Imperial College Healthcare NHS Trust · Observational
Strongyloidiasis is a worm infection which affects more than 100 million people, mostly in Africa, Asia and Latin America, and can cause severe illness in people with reduced immunity. In the UK, the number of people with Strongyloides is not known.
At Imperial College Healthcare NHS Trust (ICHNT) , screening for Stongyloides has recently been introduced as a standard-of-care for all patients undergoing BMT.
In this study, investigators will perform two cross-sectional surveys and report the prevalence of Strongyloides in BMT recipients at ICHNT , as well as comparing clinical outcomes before/after the introduction of routine testing.
Strongyloidiasis is a worm infection which affects more than 100 million people, mostly in Africa, Asia and Latin America. Infection can persist for decades, and usually causes mild symptoms. In some people with reduced immune systems (for example those who have bone marrow transplantation), the worms can multiply and cause severe illness and death.
In the UK, the number of people with Strongyloides is not known. However, in many other non-tropical countries, rates are high in immigrant populations (including those who are having bone marrow transplantation, BMT).
At ICHNT, screening for Stongyloides has recently been introduced as a standard-of-care for all patients undergoing BMT. All adult patients with forthcoming BMT at ICHNT will now be screened. Additionally, any patients who have already undergone BMT in the last two years will be screened as part of a look-back exercise as part of their clinical care.
In this study, investigators will perform two cross-sectional surveys. Those who underwent BMT between Jun 2018 - July 2020 will form a 'pre-screening group', and those between July 2020 - July 2021 will form a 'screened group'. It is anticipated that 320 participants will be included in the pre-screening group and 160 in the screened-group (total 480).
Data will be collected retrospectively and the prevalence of Strongyloides in BMT recipients at ICHNT will be reported. Comparison of clinical outcomes between the first and second groups will be undertaken, in order to determine whether the introduction of screening has had an impact.
21 studies on the registry are indexed under Strongyloidiasis; 3 are open to participants now.
Browse Strongyloidiasis studies →Imperial College Healthcare NHS Trust is the lead sponsor of 79 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals under the care of Haematology at ICHNT
Exclusion Criteria:
Individuals undergoing bone marrow transplantation Jun 2018 - July 2020
Other: None - standard of care
Individuals undergoing bone marrow transplantation July 2020 - July 2021
Other: None - standard of care
Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.
Strongyloides seropositivity
Time frame: Baseline
BMT outcome
Bloodstream infection
Time frame: Within first 12 months after BMT
BMT outcome
Respiratory disease
Time frame: Within first 12 months after BMT
BMT outcome
Clinically significant diarrhoea
Time frame: Within first 12 months after BMT
BMT outcome
CNS infection
Time frame: Within first 12 months after BMT
BMT outcome
Graft vs. host disease
Time frame: Within first 12 months after BMT
BMT outcome
Length-of-hospital-stay
Time frame: Within first 12 months after BMT
BMT outcome
Antibiotic usage (defined daily doses)
Time frame: Within first 12 months after BMT
BMT outcome
ICU admission
Time frame: Within first 12 months after BMT
BMT outcome
Strongyloides hyperinfection syndrome
Time frame: Within first 12 months after BMT
BMT outcome
Mortality
Time frame: Within first 12 months after BMT
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imperial College Healthcare NHS Trust